Table II.

Association between platelet parameters and subsequent mortality estimated by Cox proportional hazards regression models.

	Quartile 1	Quartile 2	Quartile 3	Quartile 4	P trend
Platelet levels, ×109/L	<138	138-174	174-213	$>$213
No. of death/total	25/96	10/94	10/95	4/98
Crude model	5.42 (1.89, 15.60)	2.20 (0.69, 7.02)	2.29 (0.72, 7.31)	1.00 (ref.)	<0.001
Model 1	3.86 (1.27, 11.79)	2.88 (0.86, 9.67)	2.77 (0.84, 9.10)	1.00 (ref.)	0.02
Model 2	4.24 (1.32, 13.61)	3.74 (1.06, 13.18)	3.72 (1.10, 12.53)	1.00 (ref.)	0.03
Plateletcrit, %	<0.14	0.14–0.18	0.18–0.22	$>$0.22
No. of death/total	23/86	12/103	10/91	4/103
Crude model	6.24 (2.16, 18.04)	2.51 (0.81, 7.79)	2.46 (0.77, 7.84)	1.00 (ref.)	<0.001
Model 1	4.82 (1.59, 14.57)	2.49 (0.76, 8.17)	2.51 (0.77, 8.17)	1.00 (ref.)	0.003
Model 2	6.46 (2.03, 20.56)	2.64 (0.76, 9.11)	3.00 (0.90, 10.05)	1.00 (ref.)	0.001
The mean platelet volume, fL	<9.2	9.2–10.0	10.0–10.7	$>$10.7
No. of death/total	8/87	10/101	11/93	20/102
Crude model	0.54 (0.24, 1.23)	0.57 (0.27, 1.21)	0.56 (0.27, 1.18)	1.00 (ref.)	0.11
Model 1	0.84 (0.36, 1.96)	0.53 (0.24, 1.18)	0.66 (0.30, 1.44)	1.00 (ref.)	0.35
Model 2	0.67 (0.27, 1.65)	0.49 (0.22, 1.12)	0.46 (0.19, 1.09)	1.00 (ref.)	0.22
The platelet distribution width, %	<11.0	11.0–15.5	15.5–16.4	$>$16.4
No. of death/total	11/96	16/95	9/93	13/99
Crude model	0.87 (0.39, 1.95)	1.13 (0.55, 2.36)	0.84 (0.36, 1.97)	1.00 (ref.)	0.94
Model 1	1.40 (0.61, 3.23)	2.04 (0.93, 4.50)	1.07 (0.44, 2.62)	1.00 (ref.)	0.19
Model 2	1.46 (0.62, 3.45)	2.78 (1.19, 6.45)	0.94 (0.37, 2.42)	1.00 (ref.)	0.12
The platelet larger cell ratio, %	<20	20-25	25-31	$>$31
No. of death/total	7/94	11/96	12/96	19/97
Crude model	0.41 (0.17, 0.97)	0.67 (0.32, 1.41)	0.58 (0.28, 1.20)	1.00 (ref.)	0.06
Model 1	0.74 (0.30, 1.82)	0.74 (0.34, 1.62)	0.62 (0.29, 1.30)	1.00 (ref.)	0.45
Model 2	0.69 (0.27, 1.78)	0.90 (0.39, 2.08)	0.48 (0.20, 1.14)	1.00 (ref.)	0.58

Data are presented as hazard ratios (HR) and 95% confidence intervals.

P trend was estimated using the median value of each quartile.

Model 1 adjusted for age, sex, and baseline comorbidities (including chronic obstructive pulmonary disease, hypertension, diabetes, chronic

kidney disease, cardiovascular disease, and cerebrovascular disease);

Model 2 adjusted for model 1, plus glucocorticoid therapy, intravenous immunoglobulin, blood lactate, C-reactive protein, and lymphocyte count